Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world study

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background The efficacy and safety of combining chemotherapy with different anti-PD-1 treatment as first-line treatment in advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in a real-world study remains unknown. Therefore, this real-world study investigated the efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous NSCLC. Methods Patients (n = 239) with advanced or metastatic squamous NSCLC without driver-gene mutations treated with immune checkpoint inhibitors (ICIs) as first-line treatment were retrospectively identified between October 2018 and December 2021. Results The objective response rate (ORR) and disease control rate (DCR) were 48.1% and 87.4%, respectively. The median overall survival (OS) and progression-free survival (PFS) were 26.0 and 10.0 months, respectively. The ORR in the pembrolizumab, sintilimab, camrelizumab, tislelizumab, and toripalimab groups was 52.5%, 44.7%, 50.0%, 40.3%, and 66.7%, respectively. The PFS in the pembrolizumab, sintilimab, camrelizumab, tislelizumab, and toripalimab groups was 11.5, 10.0, 8.5, 10.0, and 9.0 months, respectively (P = 0.329). The OS in the pembrolizumab, camrelizumab, and toripalimab groups was 26.0, 22.0, and 19.0 months, respectively (P = 0.967). Overall, 36.0% of patients experienced immune-related adverse events (irAEs; 12.6% of these were grade 3 or 4). The most common irAEs were nephritis (10.0%, 24/239), pneumonitis (8.8%, 21/239), and liver insufficiency (8.8%, 21/239). Patients with high baseline IL-6 levels had a significantly shorter OS than their counterparts (P = 0.021). Conclusion ICI treatment is a safe and effective first-line therapy in advanced or metastatic squamous NSCLC. Baseline serum IL-6 levels may predict treatment efficacy and survival benefit in NSCLC treated with PD-1 inhibitors.

Article activity feed